2025-11822NoticeWallet

FDA Retires Another COVID Test From Its Emergency-Use Era

Published Date: 6/26/2025

Notice

Summary

The FDA has officially ended the emergency use approval for Cepheid’s Xpert Xpress COVID-19 test as of May 28, 2025, because the company asked for it. This means the test can no longer be used under emergency rules, but it doesn’t affect other COVID-19 tests. Labs and healthcare providers should plan accordingly, but there’s no direct cost impact for the public.

Analyzed Economic Effects

1 provisions identified: 0 benefits, 0 costs, 1 mixed.

Cepheid Xpert Xpress EUA Revoked

The FDA revoked the Emergency Use Authorization (EUA) for Cepheid’s Xpert Xpress SARS-CoV-2 test effective May 28, 2025, so that specific test can no longer be used under EUA. Cepheid told FDA that all its U.S. customers transitioned to the Xpert Xpress SARS-CoV-2 plus product (authorized under EUA220187), and FDA says labs and healthcare providers should plan accordingly. FDA also stated the revocation does not affect other COVID-19 tests and has no direct cost impact for the public.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Effective Date
Published Date
5/28/2025
6/26/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register